Literature DB >> 15719069

Essential role of RSK2 in c-Fos-dependent osteosarcoma development.

Jean-Pierre David1, Denis Mehic, Latifa Bakiri, Arndt F Schilling, Vice Mandic, Matthias Priemel, Maria Helena Idarraga, Markus O Reschke, Oskar Hoffmann, Michael Amling, Erwin F Wagner.   

Abstract

Inactivation of the growth factor-regulated S6 kinase RSK2 causes Coffin-Lowry syndrome in humans, an X-linked mental retardation condition associated with progressive skeletal abnormalities. Here we show that mice lacking RSK2 develop a progressive skeletal disease, osteopenia due to impaired osteoblast function and normal osteoclast differentiation. The phenotype is associated with decreased expression of Phex, an endopeptidase regulating bone mineralization. This defect is probably not mediated by RSK2-dependent phosphorylation of c-Fos on serine 362 in the C-terminus. However, in the absence of RSK2, c-Fos-dependent osteosarcoma formation is impaired. The lack of c-Fos phosphorylation leads to reduced c-Fos protein levels, which are thought to be responsible for decreased proliferation and increased apoptosis of transformed osteoblasts. Therefore, RSK2-dependent stabilization of c-Fos is essential for osteosarcoma formation in mice and may also be important for human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719069      PMCID: PMC548699          DOI: 10.1172/JCI22877

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase.

Authors:  D R Alessi
Journal:  FEBS Lett       Date:  1997-02-03       Impact factor: 4.124

2.  Phosphorylation of c-Fos at the C-terminus enhances its transforming activity.

Authors:  R H Chen; P C Juo; T Curran; J Blenis
Journal:  Oncogene       Date:  1996-04-04       Impact factor: 9.867

3.  Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia.

Authors:  T M Strom; F Francis; B Lorenz; A Böddrich; M J Econs; H Lehrach; T Meitinger
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

4.  Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells.

Authors:  L K McCauley; A J Koh; C A Beecher; T J Rosol
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

5.  Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE.

Authors:  A T Pearman; W Y Chou; K D Bergman; M R Pulumati; N C Partridge
Journal:  J Biol Chem       Date:  1996-10-11       Impact factor: 5.157

6.  A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium.

Authors: 
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene.

Authors:  D De Cesare; S Jacquot; A Hanauer; P Sassone-Corsi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos.

Authors:  Z Q Wang; J Liang; K Schellander; E F Wagner; A E Grigoriadis
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

9.  A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets.

Authors:  M J Econs; N E Friedman; P S Rowe; M C Speer; F Francis; T M Strom; C Oudet; J A Smith; J T Ninomiya; B E Lee; H Bergen
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

10.  The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells.

Authors:  K Okazaki; N Sagata
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

View more
  31 in total

Review 1.  Targeting protein kinases with selective and semipromiscuous covalent inhibitors.

Authors:  Rand M Miller; Jack Taunton
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation.

Authors:  Kangdong Liu; Yong-Yeon Cho; Ke Yao; Janos Nadas; Dong Joon Kim; Eun-Jin Cho; Mee-Hyun Lee; Angelo Pugliese; Jishuai Zhang; Ann M Bode; Ziming Dong; Zigang Dong
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

Review 3.  Primary neoplasms of bones in mice: retrospective study and review of literature.

Authors:  A M Kavirayani; J P Sundberg; O Foreman
Journal:  Vet Pathol       Date:  2011-02-22       Impact factor: 2.221

4.  A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells.

Authors:  Eswar Shankar; Kyung Song; Sarah L Corum; Kara L Bane; Hui Wang; Hung-Ying Kao; David Danielpour
Journal:  J Biol Chem       Date:  2016-01-19       Impact factor: 5.157

Review 5.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

6.  Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis.

Authors:  L Bakiri; M O Reschke; H A Gefroh; M H Idarraga; K Polzer; R Zenz; G Schett; E F Wagner
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

7.  Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation.

Authors:  Yong-Yeon Cho; Ke Yao; Hong-Gyum Kim; Bong Seok Kang; Duo Zheng; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

8.  RSK2 as a key regulator in human skin cancer.

Authors:  Yong-Yeon Cho; Mee-Hyun Lee; Cheol-Jung Lee; Ke Yao; Hye Suk Lee; Ann M Bode; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-08-23       Impact factor: 4.944

9.  A regulatory mechanism for RSK2 NH(2)-terminal kinase activity.

Authors:  Yong-Yeon Cho; Ke Yao; Angelo Pugliese; Margarita L Malakhova; Ann M Bode; Zigang Dong
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

10.  c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.

Authors:  Xiaoping Zhang; Liang Zhang; Hongmei Yang; Xu Huang; Hasan Otu; Towia A Libermann; William C DeWolf; Roya Khosravi-Far; Aria F Olumi
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.